CABBVIE ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE ONLINE PUBLICATION OF VENETOCLAX PHASE 1 DATA IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of Medicine (NEJM) showing...
IBRUTINIB (IMBRUVICA®) COMBINATION DATA SHOW PROMISE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
AbbVie , a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®) plus carfilzomib...
IMBRUVICA® (IBRUTINIB) PHASE 3 RAY DATA SHOW SIGNIFICANT REDUCTIONS IN DISEASE PROGRESSION VERSUS TEMSIROLIMUS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS
- IMBRUVICA ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN KEY ENDPOINTS INCLUDING REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH VERSUS TEMSIROLIMUS CHEMOTHERAPY - PHASE...
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
• New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new...
Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK), known as MSD outside...
Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®
Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK),...
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...